Table 2.
Characteristics of hospitalized patients depending on occurrence of post–COVID-19 DSA
| Characteristics | Hospitalized (n = 88) |
No post–COVID-19 DSA (n = 81) |
Post–COVID-19 DSA (n = 7) |
P value | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| NA | n | % | NA | n | % | NA | n | % | ||
| Male recipient | 0 | 64 | 72.7 | 0 | 57 | 70.4 | 0 | 7 | 100 | 0.1825 |
| Calcineurin inhibitor treatment | 0 | 80 | 90.9 | 0 | 74 | 91.4 | 0 | 6 | 85.7 | 0.4996 |
| Belatacept treatment | 0 | 4 | 4.5 | 0 | 4 | 4.9 | 0 | 0 | 0 | 1 |
| mTOR inhibitor treatment | 0 | 16 | 18.2 | 0 | 16 | 19.8 | 0 | 0 | 0 | 0.3417 |
| Antimetabolite treatment | 0 | 68 | 77.3 | 0 | 63 | 77.8 | 0 | 5 | 71.4 | 0.6552 |
| Steroid treatment | 1 | 50 | 57.5 | 1 | 46 | 57.5 | 0 | 4 | 57.1 | 1 |
| Previous DSA | 0 | 7 | 8.0 | 0 | 5 | 6.2 | 0 | 2 | 28.6 | 0.0944 |
| Episode of rejection | 0 | 21 | 23.9 | 0 | 19 | 23.5 | 0 | 2 | 28.6 | 0.6699 |
| COVID-19 Pneumonia | 0 | 77 | 87.5 | 0 | 71 | 87.7 | 0 | 6 | 85.7 | 1 |
| AKI episode | 4 | 43 | 51.2 | 3 | 41 | 52.6 | 1 | 2 | 33.3 | 0.4274 |
| Requiring dialysis | 5 | 10 | 12.0 | 4 | 9 | 11.7 | 1 | 1 | 16.7 | 0.5490 |
| Intensive care unit | 0 | 21 | 23.9 | 0 | 19 | 23.5 | 0 | 2 | 28.6 | 0.6699 |
| Mechanical ventilation | 0 | 17 | 19.3 | 0 | 15 | 18.5 | 0 | 2 | 28.6 | 0.6165 |
| Use of SARS-CoV-2–specific therapy | 0 | 53 | 60.2 | 0 | 49 | 60.5 | 0 | 4 | 57.1 | 1 |
| High-dose steroids | 0 | 40 | 45.5 | 0 | 37 | 45.7 | 0 | 3 | 42.9 | 1 |
| Tocilizumab | 2 | 5 | 5.8 | 2 | 5 | 6.3 | 0 | 0 | 0 | 1 |
| Other |
0 |
29 |
33.0 |
0 |
27 |
33.3 |
0 |
2 |
28.6 |
1 |
| NA |
Mean |
SD |
NA |
Mean |
SD |
NA |
Mean |
SD |
P value |
|
| Recipient age (yr) | 1 | 57.0 | 13.9 | 1 | 58.0 | 12.8 | 0 | 45.3 | 21.4 | 0.1794 |
| Time from transplantation (yr) | 0 | 6.5 | 7.0 | 0 | 6.8 | 7.1 | 0 | 2.6 | 3.3 | 0.0610 |
| Allograft function by MDRD (ml/min) | 3 | 52.0 | 22.5 | 2 | 50.2 | 21.4 | 1 | 75.6 | 25.8 | 0.0201 |
| Creatininemia (μmol/l) | 3 | 144.0 | 56.9 | 2 | 146.2 | 57.0 | 1 | 115.4 | 51.0 | 0.1068 |
| CRP highest level (mg/l) | 7 | 80.1 | 65.4 | 6 | 80.8 | 66.4 | 1 | 72.0 | 55.1 | 0.8357 |
| Lymphocyte lowest level (/mm3) | 6 | 654.5 | 1041.4 | 5 | 655.9 | 1072.6 | 1 | 636.7 | 556.8 | 0.8100 |
| IL-6 dosage (pg/ml) | 48 | 249.3 | 1211.9 | 44 | 264.3 | 1260.1 | 4 | 65.1 | 67.0 | — |
| Time from CNI interruption | 0 | 13.7 | 11.3 | 0 | 13.9 | 11.9 | 0 | 12.7 | 9.1 | 1 |
| Time from antimetabolite interruption | 0 | 27.4 | 19.1 | 0 | 27.3 | 19.7 | 0 | 27.8 | 13.4 | 0.8407 |
AKI, acute kidney injury defined by an increase of 50% or more of basal creatininemia; BMI, body mass index; CNI, calcineurin inhibitor; CRP, C-reactive protein; DSA, donor-specific antibody; IL-6, interleukin 6; MDRD, Modification of Diet in Renal Diseases.
Bold emphasis has been used to clarify the statistical significant differences between groups.